Blockade of the K ATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy

S. Moriguchi; T. Ishizuka; Y. Yabuki; N. Shioda; Y. Sasaki; H. Tagashira; H. Yawo; J. Z. Yeh; H. Sakagami; T. Narahashi; K. Fukunaga

doi:10.1038/mp.2016.187

Blockade of the K ATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy

S. Moriguchi^*, T. Ishizuka, Y. Yabuki, N. Shioda, Y. Sasaki, H. Tagashira, H. Yawo, J. Z. Yeh, H. Sakagami, T. Narahashi, K. Fukunaga

^*Corresponding author for this work

Pharmacology

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

Here, we report a novel target of the drug memantine, ATP-sensitive K ⁺ (K _ATP ) channels, potentially relevant to memory improvement. We confirmed that memantine antagonizes memory impairment in Alzheimer's model APP23 mice. Memantine increased CaMKII activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term potentiation (LTP) and CaMKII activity was totally abolished by treatment with pinacidil, a specific opener of K _ATP channels. Memantine also inhibited Kir6.1 and Kir6.2 K _ATP channels and elevated intracellular Ca ²⁺ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Kir6.2 was preferentially expressed at postsynaptic regions of hippocampal neurons, whereas Kir6.1 was predominant in dendrites and cell bodies of pyramidal neurons. Finally, we confirmed that Kir6.2 mutant mice exhibit severe memory deficits and impaired hippocampal LTP, impairments that cannot be rescued by memantine administration. Altogether, our studies show that memantine modulates Kir6.2 activity, and that the Kir6.2 channel is a novel target for therapeutics to improve memory impairment in Alzheimer disease patients.

Original language	English (US)
Pages (from-to)	211-221
Number of pages	11
Journal	Molecular Psychiatry
Volume	23
Issue number	2
DOIs	https://doi.org/10.1038/mp.2016.187
State	Published - Feb 1 2018

Funding

This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health and Welfare of Japan (22390109 to KF; 20790398 to SM). Also, thanks to Professor Tsuyoshi Miyakawa for providing CaMKIIα +/ − mice and Professor Susumu Seino for providing Kir6.1 +/ − and Kir6.2 − / − mice. We also thank Novartis Pharma for providing APP23 mice. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health and Welfare of Japan (22390109 to KF; 20790398 to SM). Also, thanks to Professor Tsuyoshi Miyakawa for providing CaMKIIα +/-mice and Professor Susumu Seino for providing Kir6.1 +/-and Kir6.2-/-mice. We also thank Novartis Pharma for providing APP23 mice.

ASJC Scopus subject areas

Molecular Biology
Psychiatry and Mental health
Cellular and Molecular Neuroscience

Access to Document

10.1038/mp.2016.187

Cite this

@article{d9a7ec34298e4958a72195bf08817665,

title = "Blockade of the K ATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy",

abstract = " Here, we report a novel target of the drug memantine, ATP-sensitive K + (K ATP ) channels, potentially relevant to memory improvement. We confirmed that memantine antagonizes memory impairment in Alzheimer's model APP23 mice. Memantine increased CaMKII activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term potentiation (LTP) and CaMKII activity was totally abolished by treatment with pinacidil, a specific opener of K ATP channels. Memantine also inhibited Kir6.1 and Kir6.2 K ATP channels and elevated intracellular Ca 2+ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Kir6.2 was preferentially expressed at postsynaptic regions of hippocampal neurons, whereas Kir6.1 was predominant in dendrites and cell bodies of pyramidal neurons. Finally, we confirmed that Kir6.2 mutant mice exhibit severe memory deficits and impaired hippocampal LTP, impairments that cannot be rescued by memantine administration. Altogether, our studies show that memantine modulates Kir6.2 activity, and that the Kir6.2 channel is a novel target for therapeutics to improve memory impairment in Alzheimer disease patients. ",

author = "S. Moriguchi and T. Ishizuka and Y. Yabuki and N. Shioda and Y. Sasaki and H. Tagashira and H. Yawo and Yeh, {J. Z.} and H. Sakagami and T. Narahashi and K. Fukunaga",

note = "Funding Information: This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health and Welfare of Japan (22390109 to KF; 20790398 to SM). Also, thanks to Professor Tsuyoshi Miyakawa for providing CaMKIIα +/ − mice and Professor Susumu Seino for providing Kir6.1 +/ − and Kir6.2 − / − mice. We also thank Novartis Pharma for providing APP23 mice. Funding Information: This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health and Welfare of Japan (22390109 to KF; 20790398 to SM). Also, thanks to Professor Tsuyoshi Miyakawa for providing CaMKIIα +/-mice and Professor Susumu Seino for providing Kir6.1 +/-and Kir6.2-/-mice. We also thank Novartis Pharma for providing APP23 mice. Publisher Copyright: {\textcopyright} 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.",

year = "2018",

month = feb,

day = "1",

doi = "10.1038/mp.2016.187",

language = "English (US)",

volume = "23",

pages = "211--221",

journal = "Molecular Psychiatry",

issn = "1359-4184",

publisher = "Springer Nature",

number = "2",

}

TY - JOUR

T1 - Blockade of the K ATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy

AU - Moriguchi, S.

AU - Ishizuka, T.

AU - Yabuki, Y.

AU - Shioda, N.

AU - Sasaki, Y.

AU - Tagashira, H.

AU - Yawo, H.

AU - Yeh, J. Z.

AU - Sakagami, H.

AU - Narahashi, T.

AU - Fukunaga, K.

N1 - Funding Information: This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health and Welfare of Japan (22390109 to KF; 20790398 to SM). Also, thanks to Professor Tsuyoshi Miyakawa for providing CaMKIIα +/ − mice and Professor Susumu Seino for providing Kir6.1 +/ − and Kir6.2 − / − mice. We also thank Novartis Pharma for providing APP23 mice. Funding Information: This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health and Welfare of Japan (22390109 to KF; 20790398 to SM). Also, thanks to Professor Tsuyoshi Miyakawa for providing CaMKIIα +/-mice and Professor Susumu Seino for providing Kir6.1 +/-and Kir6.2-/-mice. We also thank Novartis Pharma for providing APP23 mice. Publisher Copyright: © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Here, we report a novel target of the drug memantine, ATP-sensitive K + (K ATP ) channels, potentially relevant to memory improvement. We confirmed that memantine antagonizes memory impairment in Alzheimer's model APP23 mice. Memantine increased CaMKII activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term potentiation (LTP) and CaMKII activity was totally abolished by treatment with pinacidil, a specific opener of K ATP channels. Memantine also inhibited Kir6.1 and Kir6.2 K ATP channels and elevated intracellular Ca 2+ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Kir6.2 was preferentially expressed at postsynaptic regions of hippocampal neurons, whereas Kir6.1 was predominant in dendrites and cell bodies of pyramidal neurons. Finally, we confirmed that Kir6.2 mutant mice exhibit severe memory deficits and impaired hippocampal LTP, impairments that cannot be rescued by memantine administration. Altogether, our studies show that memantine modulates Kir6.2 activity, and that the Kir6.2 channel is a novel target for therapeutics to improve memory impairment in Alzheimer disease patients.

AB - Here, we report a novel target of the drug memantine, ATP-sensitive K + (K ATP ) channels, potentially relevant to memory improvement. We confirmed that memantine antagonizes memory impairment in Alzheimer's model APP23 mice. Memantine increased CaMKII activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term potentiation (LTP) and CaMKII activity was totally abolished by treatment with pinacidil, a specific opener of K ATP channels. Memantine also inhibited Kir6.1 and Kir6.2 K ATP channels and elevated intracellular Ca 2+ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Kir6.2 was preferentially expressed at postsynaptic regions of hippocampal neurons, whereas Kir6.1 was predominant in dendrites and cell bodies of pyramidal neurons. Finally, we confirmed that Kir6.2 mutant mice exhibit severe memory deficits and impaired hippocampal LTP, impairments that cannot be rescued by memantine administration. Altogether, our studies show that memantine modulates Kir6.2 activity, and that the Kir6.2 channel is a novel target for therapeutics to improve memory impairment in Alzheimer disease patients.

UR - http://www.scopus.com/inward/record.url?scp=84992390024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992390024&partnerID=8YFLogxK

U2 - 10.1038/mp.2016.187

DO - 10.1038/mp.2016.187

M3 - Article

C2 - 27777420

AN - SCOPUS:84992390024

SN - 1359-4184

VL - 23

SP - 211

EP - 221

JO - Molecular Psychiatry

JF - Molecular Psychiatry

IS - 2

ER -

Blockade of the K ATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this